<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03542123</url>
  </required_header>
  <id_info>
    <org_study_id>700003-02</org_study_id>
    <nct_id>NCT03542123</nct_id>
  </id_info>
  <brief_title>Cardiac Output Autonomic Stimulation Therapy for Heart Failure - Hemodynamic Effects</brief_title>
  <acronym>COAST-HF FX</acronym>
  <official_title>Cardiac Output Autonomic Stimulation Therapy for Heart Failure - Hemodynamic Effects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NeuroTronik Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NeuroTronik Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single-arm study to observe NeuroTronik Cardiac Autonomic Nerve Stimulation (CANS) Therapy
      System hemodynamic and other physiologic effects.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 5, 2018</start_date>
  <completion_date type="Anticipated">July 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Left ventricular pressure and volume</measure>
    <time_frame>One hour</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>One hour</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Heart Failure Acute</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>NeuroTronik CANS Therapy® System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NeuroTronik CANS Therapy® System</intervention_name>
    <description>The NeuroTronik CANS Therapy® System is a percutaneous, catheter-based, bedside electrical stimulation system. The System consists of the single-use, disposable NeuroCatheter™ and NeuroCatheter™ Placement Kit, along with the reusable, bedside NeuroModulator™ Development System, and the NeuroTronik CANS Therapy™ Cable.</description>
    <arm_group_label>NeuroTronik CANS Therapy® System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Normal sinus rhythm by ECG

          -  Men and women 21-75 years old

          -  Patients with stable symptomatic heart failure, New York Heart Association (NYHA)
             class II, III, or IV.

        Exclusion Criteria:

          -  Systolic Blood Pressure &lt; 90 mmHg or &gt; 160 mmHg

          -  Current amiodarone therapy or any other antiarrhythmic therapy

          -  Coronary artery bypass graft surgery or percutaneous coronary intervention within
             prior 1 month

          -  Enzyme-positive MI within prior 1 month

          -  Patients who have been hospitalized for heart failure and who required the use of HF
             IV therapy within 30 days before enrollment (measured from release)

          -  History of recent severe ventricular arrhythmias

          -  Pre-existing carotid artery or cerebral disease

          -  Patients with hypertrophic obstructive cardiomyopathy or infiltrative cardiomyopathy
             (e.g. amyloidosis, sarcoidosis)

          -  Patients with prior vagalotomy

          -  Patients with current or prior vagal nerve stimulators

          -  Subjects with narrow angle glaucoma

          -  Renal failure - on dialysis or serum creatinine &gt; 2.0 mg/dl

          -  Hepatic failure - bilirubin, SGOT, or SGPT &gt; 4X upper limit of normal

          -  Patients with a life expectance &lt; 12 months per physician judgment

          -  Women who are pregnant

          -  Allergy to fentanyl, midazolam, propofol, eggs, egg products, soybeans, or soy
             products

          -  Subjects unwilling or unable to provide consent for the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Adrian Ebner, Medical Doctor</last_name>
    <phone>011 595 21 202767</phone>
    <email>adrian_ebner@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sanatorio Italiano</name>
      <address>
        <city>Asunción</city>
        <country>Paraguay</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adrian Ebner, MD</last_name>
      <phone>011 595 21 202767</phone>
      <email>adrian_ebner@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Adrian Ebner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Paraguay</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>May 18, 2018</study_first_submitted>
  <study_first_submitted_qc>May 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 31, 2018</study_first_posted>
  <last_update_submitted>August 22, 2018</last_update_submitted>
  <last_update_submitted_qc>August 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Electrical Stimulation Therapy; Electrodes; Parasympathetic Nervous System; Sympathetic Fibers, Post Ganglionic; Congestive Heart Failure; Heart Failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

